Considering the Acquisition of Domestic and Overseas Cell Therapy Product Pipelines
First written in FY2016-Q3. 19 of 27 entries say "Restated". Latest entry: 2026-10-16.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2025-H1ReframedAnnual report
「Going forward, in addition to seeking to acquire development candidates to replace α-GalCer/DC at an early stage, we will monitor development trends for regenerative medicine products in Japan and overseas and acquire and expand those pipelines.」
Following the discontinuation of development of α-GalCer/DC, the policy changed from that program to the early acquisition of alternative development candidates and the acquisition and expansion of pipelines. - FY2023RestatedAnnual report
「We are also monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to expanding the pipeline through alliances with companies and other organizations in Japan and overseas that possess promising technologies, materials and other assets.」
The company continues to consider expanding its regenerative medicine product pipeline through alliances with companies and other organizations in Japan and overseas. - FY2023-Q3RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization of regenerative medicine products and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2023-Q2RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization of regenerative medicine products and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2023-Q1RestatedAnnual report
「In the regenerative medicine products business, we aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization of regenerative medicine products and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2022-Q3RestatedAnnual report
「In the regenerative medicine products business, we aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2022-Q2RestatedAnnual report
「In the regenerative medicine products business, we aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization of regenerative medicine products and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2022-Q1RestatedAnnual report
「In the regenerative medicine products business, we aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization of regenerative medicine products and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2021-Q3RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering early monetization of regenerative medicine products and pipeline acquisitions and expansion in Japan and overseas has continued. - FY2021-Q2RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering pipeline acquisitions and expansion for regenerative medicine products and early monetization has continued. - FY2021-Q1RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering pipeline acquisitions and expansion for regenerative medicine products in Japan and overseas and early monetization has continued. - FY2020-Q3RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering pipeline acquisitions and expansion for regenerative medicine products and early monetization has continued. - FY2020-Q1AdvancedAnnual report
「As a development seed to follow “MDNT01” and “ATL-DC-101,” we concluded a joint research agreement with Kyushu University, a national university corporation, aimed at commercializing a regenerative medicine product for the treatment of chronic heart failure.」
As a development seed following the existing products, the company concluded a joint research agreement for a regenerative medicine product for chronic heart failure, adding a specific activity aimed at expanding the pipeline. - FY2019Made more specific as the selection of candidates for early commercializationAnnual report
「We have continued discussions with companies in Japan and overseas and with academia in order to select development seeds capable of early commercialization to follow MDNT01 and ATL-DC-101.」
Regarding the policy of acquiring and expanding the pipeline, the company reported the specific activity of selecting development seeds capable of early commercialization to follow MDNT01 and ATL-DC-101. - FY2019-Q3RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering pipeline acquisitions and expansion for regenerative medicine products and early monetization has continued. - FY2019-Q2RestatedAnnual report
「We aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of considering pipeline acquisitions and expansion and early monetization has continued. - FY2019-Q1RestatedAnnual report
「In the regenerative medicine products business, we aim to monetize regenerative medicine products at an early stage while monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring and expanding those pipelines.」
The policy of aiming for early monetization while considering pipeline acquisitions and expansion has continued. - FY2018-Q2RestatedAnnual report
「We are also monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring their pipelines.」
The policy of considering pipeline acquisitions for regenerative medicine products in Japan and overseas has continued. - FY2018-Q1RestatedAnnual report
「In the regenerative medicine products business, we aim to commercialize regenerative medicine products through ongoing joint research with university hospitals and other institutions. We are also monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring their pipelines.」
The policy of considering pipeline acquisitions based on development trends for regenerative medicine products in Japan and overseas has continued. - FY2017RestatedAnnual report
「We will expand our development pipeline and accelerate the development of cell therapy products through alliances with companies and other organizations in Japan and overseas that possess promising cell therapy product seeds.」
In addition to the previous exploration policy, the company has explicitly stated that it will expand its pipeline through alliances with companies possessing promising seeds in Japan and overseas. - FY2017-Q3RestatedAnnual report
「Segment loss was ¥601 million due to R&D investment in the discovery of seeds leading to cell therapy products, technology improvements and securing intellectual property rights, among other activities.」
The search for product candidates and pipeline formation through seed discovery, technology improvements and securing intellectual property rights have continued. - FY2017-Q2RestatedAnnual report
「Segment loss was ¥512 million due to R&D investment in the discovery of seeds leading to cell therapy products, technology improvements and securing intellectual property rights, among other activities.」
The search for cell therapy product candidates has continued as an R&D activity, together with technology improvements and securing intellectual property rights. - FY2017-Q1ReframedAnnual report
「We are also working to identify promising product candidates in Japan and overseas.」
The wording has been made more specific and changed from considering the acquisition of pipelines in Japan and overseas to considering the identification of promising product candidates and pipeline expansion. - FY2016-Q3First statedAnnual report
「We are also monitoring cell therapy product development trends in Japan and overseas and pursuing activities with a view to acquiring those pipelines.」
The Company is pursuing activities with a view to acquiring cell therapy product pipelines in Japan and overseas.